These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 22382255

  • 1. A review of interferon use in patients with relapsing remitting multiple sclerosis in the Canterbury region, New Zealand: 2000-2006.
    Byrne S, Mason D.
    N Z Med J; 2012 Feb 24; 125(1350):37-44. PubMed ID: 22382255
    [Abstract] [Full Text] [Related]

  • 2. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M, Sørensen PS, Andersson M, Celius EG, Jongen PJ, Elovaara I, Bartholomé E, Constantinescu CS, Beer K, Garde E, Sperling B.
    Lancet Neurol; 2010 Jul 24; 9(7):672-80. PubMed ID: 20542736
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis.
    O'Rourke K, Walsh C, Antonelli G, Hutchinson M.
    Mult Scler; 2007 Apr 24; 13(3):336-42. PubMed ID: 17439902
    [Abstract] [Full Text] [Related]

  • 5. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J, Rovira A, Tintoré M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X.
    Mult Scler; 2008 May 24; 14(4):479-84. PubMed ID: 18562504
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. New natural history of interferon-beta-treated relapsing multiple sclerosis.
    Trojano M, Pellegrini F, Fuiani A, Paolicelli D, Zipoli V, Zimatore GB, Di Monte E, Portaccio E, Lepore V, Livrea P, Amato MP.
    Ann Neurol; 2007 Apr 24; 61(4):300-6. PubMed ID: 17444502
    [Abstract] [Full Text] [Related]

  • 8. Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis.
    Portaccio E, Zipoli V, Siracusa G, Sorbi S, Amato MP.
    Eur Neurol; 2008 Apr 24; 59(3-4):131-5. PubMed ID: 18057899
    [Abstract] [Full Text] [Related]

  • 9. Assessing disability progression with the Multiple Sclerosis Functional Composite.
    Rudick RA, Polman CH, Cohen JA, Walton MK, Miller AE, Confavreux C, Lublin FD, Hutchinson M, O'Connor PW, Schwid SR, Balcer LJ, Lynn F, Panzara MA, Sandrock AW.
    Mult Scler; 2009 Aug 24; 15(8):984-97. PubMed ID: 19667023
    [Abstract] [Full Text] [Related]

  • 10. [Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].
    Mezei Z, Bereczki D, Csiba L, Csépány T.
    Ideggyogy Sz; 2006 Nov 20; 59(11-12):442-7. PubMed ID: 17203882
    [Abstract] [Full Text] [Related]

  • 11. Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up.
    Rudick RA, Lee JC, Cutter GR, Miller DM, Bourdette D, Weinstock-Guttman B, Hyde R, Zhang H, You X.
    Arch Neurol; 2010 Nov 20; 67(11):1329-35. PubMed ID: 20625068
    [Abstract] [Full Text] [Related]

  • 12. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
    Pokryszko-Dragan A, Bilińska M, Gruszka E, Dubik-Jezierzańska M.
    Pol Merkur Lekarski; 2005 Nov 20; 19(113):654-8. PubMed ID: 16498805
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon.
    Bosca I, Coret F, Valero C, Pascual AM, Magraner MJ, Landete L, Casanova B.
    Mult Scler; 2008 Jun 20; 14(5):636-9. PubMed ID: 18566027
    [Abstract] [Full Text] [Related]

  • 16. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
    Saida T, Tashiro K, Itoyama Y, Sato T, Ohashi Y, Zhao Z, Interferon Beta-1b Multiple Sclerosis Study Group of Japan.
    Neurology; 2005 Feb 22; 64(4):621-30. PubMed ID: 15728282
    [Abstract] [Full Text] [Related]

  • 17. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials.
    Río J, Nos C, Tintoré M, Borrás C, Galán I, Comabella M, Montalban X.
    Ann Neurol; 2002 Oct 22; 52(4):400-6. PubMed ID: 12325067
    [Abstract] [Full Text] [Related]

  • 18. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr 22; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 19. Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.
    Cohen JA, Calabresi PA, Chakraborty S, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Imrey PB, Ivancic DM, Mandell BF, Perryman JE, Scott TF, Skaramagas TT, Zhang H, ACT Investigators.
    Mult Scler; 2008 Apr 22; 14(3):370-82. PubMed ID: 18208877
    [Abstract] [Full Text] [Related]

  • 20. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Goretti B, Caniatti L, Di Monte E, Ferrazza P, Brescia Morra V, Lo Fermo S, Picconi O, Luccichenti G, COGIMUS Study Group.
    Mult Scler; 2009 Jul 22; 15(7):779-88. PubMed ID: 19542262
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.